



## Immuron to Recommence Trading as IMC

**Melbourne, Australia – 27 November 2014:** Australian biopharmaceutical company Immuron Limited (ASX: IMC) confirms that in accordance with the timetable detailed in the Notice of Annual General Meeting, the Company's securities will recommence trading under the ASX Code IMC on the Australian Securities Exchange (ASX) today.

Completion of the share consolidation on a 40:1 basis as announced on 17 November 2014, does not affect the value of shareholdings, nor the total market capitalisation value of the Company, which remains the same.

The price of each share has increased by a multiple of 40 and the number of shares owned has decreased by a multiple of 40.

If you have any queries in relation to your security holding, please contact the Company's share registry, Security Transfer Registrars on +61 (0)8 9315 2333 or [registrar@securitytransfer.com.au](mailto:registrar@securitytransfer.com.au).

### **Contacts:**

Amos Meltzer, Chief Executive Officer  
+61 (0)437 587 680

Investor Relations  
Gabriella Hold, Buchan Consulting  
+61 (0)3 9866 4722

**Websites:** [www.immuron.com](http://www.immuron.com) and [www.travelan.com](http://www.travelan.com)

### **About Immuron**

Immuron is a biopharmaceutical company focused on oral immunotherapy treatments using dairy-derived antibody products for humans. Immuron's technology platform products all have a very high safety profile. The company's current products and product candidates address infectious diseases of the gastrointestinal tract as well as chronic diseases. Immuron has an on-market product, Travelan®, for preventing travellers' diarrhoea. Immuron also has a phase 2 clinical product candidate for the treatment of inflamed fatty liver disease, known as Non-Alcoholic Steatohepatitis or NASH. Immuron's main scientific alliances are with Hadassah Medical Center (Israel) and Monash University (Australia).